Get the Stockscreener App
1.61
1.83%
-0.03
After Hours:
1.62
0.01
+0.62%
Regulus Therapeutics Inc Stock (RGLS) Latest News
Victory Capital Management Inc. Has $626,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences - Quantisnow
Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $10.80 - MarketBeat
Regulus Therapeutics Reports Q3 2024 Financial Results - TipRanks
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - GuruFocus.com
Annovis Bio (NYSE:ANVS) versus Regulus Therapeutics (NASDAQ:RGLS) Head-To-Head Contrast - Defense World
RA Capital Management's Strategic Reduction in Regulus Therapeutics Holdings - GuruFocus.com
Biotechnology Value Fund L.P. Increases Stake in Regulus Therape - GuruFocus.com
What is HC Wainwright’s Estimate for RGLS FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for RGLS Issued By HC Wainwright - MarketBeat
Creative Planning Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from HC Wainwright - MarketBeat
Regulus: Q3 Earnings Snapshot - San Francisco Chronicle
Regulus Therapeutics (RGLS) Stock Price, News & Analysis - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Regulus Therapeuti - GuruFocus.com
HC Wainwright Reiterates Buy Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Yahoo Finance
Regulus Therapeutics secures exclusive license for kidney disease treatment - Investing.com India
Regulus Therapeutics secures exclusive license for kidney disease treatment By Investing.com - Investing.com South Africa
Regulus Therapeutics Inc. Enters into Patent & Technology License Agreement with the Board of Regents of the University of Texas System - Marketscreener.com
Financial Survey: Regulus Therapeutics (NASDAQ:RGLS) & Ironwood Pharmaceuticals (NASDAQ:IRWD) - Defense World
Renaissance Technologies LLC Has $211,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
RGLSRegulus Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire
Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80 - MarketBeat
Company’s Banking Stock: Dissecting a -7.22% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Regulus Therapeutics Inc [RGLS] stock for 7,280 USD was acquired by Collier Kathryn J - Knox Daily
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by CVI Holdings LLC - MarketBeat
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth - Simply Wall St
ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World
Investing in Regulus Therapeutics Inc (RGLS) Is Getting More Attractive - Knox Daily
Victory Capital Management Inc. Has $645,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by StockNews.com - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Upgraded to "Sell" by StockNews.com - MarketBeat
Oppenheimer’s latest rating for RGLS stock - Knox Daily
RGLS stock rated an Outperform by Oppenheimer - Knox Daily
Gaining Ground: Regulus Therapeutics Inc (RGLS) Closes Lower at 1.46, Down -6.41 - The Dwinnex
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Regulus Therapeutics (NASDAQ:RGLS) Raised to Sell at StockNews.com - MarketBeat
Regulus Therapeutics Inc [RGLS] Director makes an insider purchase of 4,000 shares worth 7280.0. - Knox Daily
Regulus Therapeutics Inc (RGLS) rating initates by Oppenheimer - Knox Daily
How does Regulus Therapeutics Inc (RGLS) change from a tortoise to a hare? - SETE News
Regulus Therapeutics Inc (RGLS) stock analysis: A comprehensive overview - US Post News
Regulus Therapeutics Inc (RGLS)’s stock chart: A technical perspective - US Post News
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - StockTitan
The Attractiveness of Investing In Regulus Therapeutics Inc (RGLS) is Growing - Knox Daily
Market Recap: Regulus Therapeutics Inc (RGLS)’s Positive Momentum, Closing at 1.59 - The Dwinnex
A Guide To The Risks Of Investing In Regulus Therapeutics Inc (RGLS) - Knox Daily
Vanguard Group Inc. Has $2.13 Million Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Regulus Therapeutics Reports Second Quarter 2024 Financial Resul - GuruFocus.com
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Longview News-Journal
Oppenheimer Reiterates “Outperform” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):